13:00–14:00

Plenary
Room

Industry Lunch Symposium – Novartis

Early Intervention and Disease Modification in HS: Can We Change the Course of the Disease

Welcome and Introductions
Prof. John Ingram

The pathophysiology and disease variability of HS: a window for early intervention
Dr Kelsey van Straalen

Guideline implementation, and practical approaches to early diagnosis and intervention
Dr Antonio Martorell

Guideline implementation, and practical approaches to early diagnosis and intervention
Prof. John Ingram

Panel discussion

14:15–15:15

Plenary
Room

Industry Lunch Symposium – UCB

Unveiling the role of dual inhibition of IL-17A and IL-17F in HS

Welcome and Introductions
Assoc. Professor Rūta Gancevičienė

How do IL-17A and IL-17F impact HS?
Dr John Ingram

What are the latest bimekizumab clinical data?
Prof. Jacek Szepietowski

How does bimekizumab’s efficacy translate to clinical practice?
Dr Sylke Schneider-Burrus

Panel discussion

12:45–13:45

Plenary
Room

Industry Symposium – AbbVie

New Frontiers in Hidradenitis Suppurativa

Welcome and Introductions
Dr Tadas Raudonis

What is front of mind for our patients’ needs?
Assoc. Professor Dr Marni Wiseman

New frontiers in HS pathogenesis
Dr Laura Savage

How can we be pioneers in HS patient care?
Dr Marni Wiseman
Dr Laura Savage

Panel discussion